Literature DB >> 28739705

Metabolic Rather than Pathological Response to Preoperative Chemoradiotherapy Is a Stronger Predictor of Survival in cStage IIB-IV Esophageal Cancer.

Satoru Motoyama1, Yusuke Sato2, Kiyotomi Maruyama2, Shuetsu Usami2, Kei Yoshino2, Toshinobu Nakatsu2, Tomohiko Sasaki2, Akiyuki Wakita2, Yuta Kawakita2, Jiajia Liu2, Akira Anbai3, Kouichi Ishiyama3, Hajime Saito2, Yoshihiro Minamiya2.   

Abstract

AIM: We investigated which is the stronger predictor, pathological response or metabolic response, for survival outcome in patients treated with neoadjuvant chemoradiotherapy (NACRT) plus esophagectomy for thoracic esophageal squamous cell carcinoma (TESCC). PATIENTS AND METHODS: Fifty consecutive patients with cStage IIB-IV TESCC were enrolled. We analyzed the pathological response and metabolic response (fractional decrease in tumor maximum standardized uptake value) to NACRT. Independent prognostic factors predictive of 3-year survival were investigated using univariate and multivariate analyses.
RESULTS: Among the 50 patients, 10 (20%) showed a pathological complete response (in both tumor and lymph nodes) and 36 (72%) showed grade 2-3 pathological response. Univariate analysis showed that age, gender, cT stage, pathological response and metabolic response to be significant prognostic factors. A subsequent multivariate analysis confirmed metabolic response and gender to be significant prognostic factors.
CONCLUSION: Metabolic response for NACRT was an independent prognostic factor and a more powerful predictor of survival compared to pathological response. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Neoadjuvant chemoradiotherapy; esophageal cancer; esophagectomy; metabolic response; survival

Mesh:

Year:  2017        PMID: 28739705     DOI: 10.21873/anticanres.11808

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  PET-Uptake Reduction into Lymph Nodes After Neoadjuvant Therapy is Highly Predictive of Prognosis for Patients Who have Thoracic Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy Plus Esophagectomy.

Authors:  Yushi Nagaki; Satoru Motoyama; Yusuke Sato; Akiyuki Wakita; Hiromu Fujita; Kohei Kemuriyama; Yoshihiro Sasaki; Kazuhiro Imai; Eri Maeda; Yoshihiro Minamiya
Journal:  Ann Surg Oncol       Date:  2021-08-05       Impact factor: 5.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.